Seeking Alpha

Nordion (NDZ +9%) ramps higher this morning after the company says it will divest its Target...

Nordion (NDZ +9%) ramps higher this morning after the company says it will divest its Target Therapies business to BTG for around $200M. That means, after fees, NDZ should rake-in nearly $185M on the closing. The sale its part of the company's larger strategic reorganization, and it's hefty price tag for a business whose sole product is its targeted liver cancer therapy, TheraSphere.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs